Article Text

Download PDFPDF
Availability of anti-VEGF agents for the management of advanced diabetic retinopathy in the NHS
  1. Adeela Malik,
  2. Hadi Zambarakji
  1. The Eye Treatment Centre, Barts Health NHS Trust, Whipps Cross University Hospital, London, UK
  1. Correspondence to Dr Adeela Malik, The Eye Treatment Centre, Barts Health NHS Trust, Whipps Cross University Hospital, Whipps Cross Road, London E11 1NR, UK; adeela15malik{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The anti-vascular endothelial growth factor (anti-VEGF) drug Bevacizumab (Avastin Genentech Inc. (Roche Group), San Francisco, California, USA) has been in circulation for several years within the ophthalmic community. Numerous studies have reported clinical outcomes of Bevacizumab in the context of proliferative diabetic retinopathy (PDR)1–4 and neovascular glaucoma. These, including a comprehensive review5 and a meta-analysis,6 have all reported favourable clinical outcomes. Studies therefore confirm that Bevacizumab reduces the risk of haemorrhage, reduces the need for endodiathermy, facilitates surgery and reduces surgical time if administered days prior to vitrectomy surgery for PDR. Bevacizumab also reduces retinal neovascularisation and/or iris neovascularisation in patients with rubeotic glaucoma secondary to advanced PDR when used …

View Full Text


  • Contributors AM and HZ compiled the document and identified the relevant statistical data.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.